Nucl Med Mol Imaging.  2018 Oct;52(5):384-388. 10.1007/s13139-018-0538-5.

Role of Positron Emission Tomography as a Biologic Marker in the Diagnosis of Primary Progressive Aphasia: Two Case Reports

• Jeong YJ
• Park KW
• Kang DY

• KMID: 2422801
• DOI: http://doi.org/10.1007/s13139-018-0538-5

Abstract

Primary progressive aphasia (PPA) is a heterogenous neurodegenerative disorder characterized by declining language and speech ability. Various underlying neuropathologies can induce PPA, and the disorder is divided into three subtypes"”progressive non-fluent aphasia, semantic variant aphasia, and logopenic aphasia"”according to clinical features. Accurate disease classification and prediction of underlying diseases are necessary for appropriate treatment, but proper use of imaging tests is important because clinical information alone often makes it difficult to make accurate decisions. Because there is a characteristic metabolic pattern according to the subtypes, F-18 fluorodeoxyglucose positron emission tomography (PET) can indicate subtype classification. In addition, PETstudies for imaging amyloid or dopamine transporters play an important role in demonstrating underlying disease. The present case showed that PET imaging studies are useful in diagnosis and could be used as a biomarker in PPA.

Keyword

Primary progressive aphasia; Positron emission tomography; Fluorodeoxyglucose; Amyloid; Dopamine transporter; Biomarker

MeSH Terms

Amyloid
Aphasia
Aphasia, Primary Progressive*
Biomarkers*
Classification
Diagnosis*
Dopamine
Dopamine Plasma Membrane Transport Proteins
Electrons*
Neurodegenerative Diseases
Neuropathology
Positron-Emission Tomography*
Amyloid
Biomarkers
Dopamine
Dopamine Plasma Membrane Transport Proteins